Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer

Sung Uk Bae, Woon Kyung Jeong, Seong Kyu Baek, Nam Kyu Kim, Ilseon Hwang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The present study evaluated the association between programmed cell death ligand-1 (PD-L1) expression and long-term oncologic outcomes in colorectal cancer (CRC). PD-L1 expression was evaluated using immunohistochemistry in 175 patients who underwent surgical resection for CRC between September 1999 and August 2004. Patients were grouped according to PD-L1 expression, with 82 (46.9%) and 93 (53.1%) in the low and high PD-L1 expression groups, respectively. The overall survival (OS) and disease-free survival (DFS) rates were significantly better in the high expression group compared with in the low expression group (OS: 48.2 vs. 32.9%, P=0.047; DFS: 43.3 vs. 32.9%, P=0.021). According to the Tumor-Node-Metastasis stage subgroups, the OS rates in the low and high expression groups, respectively, were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.789), 19.6 and 51.1% in stage III (P=0.011) and 9.1 and 0% in stage IV (P=0.005). The DFS rates in the low and high expression groups, respectively, were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.857), 19.6 and 38.3% in stage III (P=0.006) and 9.1 and 0% in stage IV (P=0.700). The systemic recurrence rate was significantly higher in the low expression group compared with in the high expression group (42.7 vs. 12.9%, respectively, P=0.030). Low PD-L1 expression was significantly associated with tumor relapse and poor prognosis in stage III CRC.

Original languageEnglish
Pages (from-to)5214-5222
Number of pages9
JournalOncology Letters
Volume16
Issue number4
DOIs
Publication statusPublished - 2018 Oct

Fingerprint

Colorectal Neoplasms
Cell Death
Ligands
Disease-Free Survival
Survival Rate
Recurrence
Survival
Neoplasms
Immunohistochemistry
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Bae, Sung Uk ; Jeong, Woon Kyung ; Baek, Seong Kyu ; Kim, Nam Kyu ; Hwang, Ilseon. / Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer. In: Oncology Letters. 2018 ; Vol. 16, No. 4. pp. 5214-5222.
@article{9f30bc340caf4a818baf1bb7ab876d87,
title = "Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer",
abstract = "The present study evaluated the association between programmed cell death ligand-1 (PD-L1) expression and long-term oncologic outcomes in colorectal cancer (CRC). PD-L1 expression was evaluated using immunohistochemistry in 175 patients who underwent surgical resection for CRC between September 1999 and August 2004. Patients were grouped according to PD-L1 expression, with 82 (46.9{\%}) and 93 (53.1{\%}) in the low and high PD-L1 expression groups, respectively. The overall survival (OS) and disease-free survival (DFS) rates were significantly better in the high expression group compared with in the low expression group (OS: 48.2 vs. 32.9{\%}, P=0.047; DFS: 43.3 vs. 32.9{\%}, P=0.021). According to the Tumor-Node-Metastasis stage subgroups, the OS rates in the low and high expression groups, respectively, were 66.7 and 60.0{\%} in stage I (P=0.715), 51.8 and 46.7{\%} in stage II (P=0.789), 19.6 and 51.1{\%} in stage III (P=0.011) and 9.1 and 0{\%} in stage IV (P=0.005). The DFS rates in the low and high expression groups, respectively, were 66.7 and 60.0{\%} in stage I (P=0.715), 51.8 and 46.7{\%} in stage II (P=0.857), 19.6 and 38.3{\%} in stage III (P=0.006) and 9.1 and 0{\%} in stage IV (P=0.700). The systemic recurrence rate was significantly higher in the low expression group compared with in the high expression group (42.7 vs. 12.9{\%}, respectively, P=0.030). Low PD-L1 expression was significantly associated with tumor relapse and poor prognosis in stage III CRC.",
author = "Bae, {Sung Uk} and Jeong, {Woon Kyung} and Baek, {Seong Kyu} and Kim, {Nam Kyu} and Ilseon Hwang",
year = "2018",
month = "10",
doi = "10.3892/ol.2018.9264",
language = "English",
volume = "16",
pages = "5214--5222",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "4",

}

Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer. / Bae, Sung Uk; Jeong, Woon Kyung; Baek, Seong Kyu; Kim, Nam Kyu; Hwang, Ilseon.

In: Oncology Letters, Vol. 16, No. 4, 10.2018, p. 5214-5222.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer

AU - Bae, Sung Uk

AU - Jeong, Woon Kyung

AU - Baek, Seong Kyu

AU - Kim, Nam Kyu

AU - Hwang, Ilseon

PY - 2018/10

Y1 - 2018/10

N2 - The present study evaluated the association between programmed cell death ligand-1 (PD-L1) expression and long-term oncologic outcomes in colorectal cancer (CRC). PD-L1 expression was evaluated using immunohistochemistry in 175 patients who underwent surgical resection for CRC between September 1999 and August 2004. Patients were grouped according to PD-L1 expression, with 82 (46.9%) and 93 (53.1%) in the low and high PD-L1 expression groups, respectively. The overall survival (OS) and disease-free survival (DFS) rates were significantly better in the high expression group compared with in the low expression group (OS: 48.2 vs. 32.9%, P=0.047; DFS: 43.3 vs. 32.9%, P=0.021). According to the Tumor-Node-Metastasis stage subgroups, the OS rates in the low and high expression groups, respectively, were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.789), 19.6 and 51.1% in stage III (P=0.011) and 9.1 and 0% in stage IV (P=0.005). The DFS rates in the low and high expression groups, respectively, were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.857), 19.6 and 38.3% in stage III (P=0.006) and 9.1 and 0% in stage IV (P=0.700). The systemic recurrence rate was significantly higher in the low expression group compared with in the high expression group (42.7 vs. 12.9%, respectively, P=0.030). Low PD-L1 expression was significantly associated with tumor relapse and poor prognosis in stage III CRC.

AB - The present study evaluated the association between programmed cell death ligand-1 (PD-L1) expression and long-term oncologic outcomes in colorectal cancer (CRC). PD-L1 expression was evaluated using immunohistochemistry in 175 patients who underwent surgical resection for CRC between September 1999 and August 2004. Patients were grouped according to PD-L1 expression, with 82 (46.9%) and 93 (53.1%) in the low and high PD-L1 expression groups, respectively. The overall survival (OS) and disease-free survival (DFS) rates were significantly better in the high expression group compared with in the low expression group (OS: 48.2 vs. 32.9%, P=0.047; DFS: 43.3 vs. 32.9%, P=0.021). According to the Tumor-Node-Metastasis stage subgroups, the OS rates in the low and high expression groups, respectively, were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.789), 19.6 and 51.1% in stage III (P=0.011) and 9.1 and 0% in stage IV (P=0.005). The DFS rates in the low and high expression groups, respectively, were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.857), 19.6 and 38.3% in stage III (P=0.006) and 9.1 and 0% in stage IV (P=0.700). The systemic recurrence rate was significantly higher in the low expression group compared with in the high expression group (42.7 vs. 12.9%, respectively, P=0.030). Low PD-L1 expression was significantly associated with tumor relapse and poor prognosis in stage III CRC.

UR - http://www.scopus.com/inward/record.url?scp=85052368609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052368609&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.9264

DO - 10.3892/ol.2018.9264

M3 - Article

AN - SCOPUS:85052368609

VL - 16

SP - 5214

EP - 5222

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

ER -